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Objective. To determine whether increases in heart rates (HRs) over time leads to adverse cardiovascular (CV) events among
“healthysubjects.” Methods.Thisretrospective cohortstudy usedtheGECentricity EMRdatabase.“Healthysubjects” were deﬁned
asthosewithCharlsonComorbidityIndex(CCI)score=0andChronicDiseaseScore(CDS)=0atbaseline.Subjects were followed
for 3 years post the ﬁrst date of a clinical encounter between the patient and provider. Those aged ≥ 18 years old with baseline HR
and ≥ 2 post-index HR readings were identiﬁed between 01/01/1996 to 03/30/2007. Results. There were 93,952 “healthy subjects”
atbaseline(median age42 years;67.2%women;mean HR was 75.8(SD:11) bpm);20.7%witha mean HR atbaseline of76.3(SD:
11.3)bpm (medianage45;63women)experienced a CVevent during3years offollow-up.The mean HR washigheramongthose
with a CV event (76.3 bmp) compared to those without a CV event (75.7 bpm). A Cox regression model indicated that an increase
in HR by 5 bpm was associated with a 1% increase in CV event risk. Conclusions. Elevated HRs are associated with an increased
likelihood of CV events among“healthy subjects”.
1.Introduction
Several studies on diﬀerent patient population shave linked
high heart rates (HRs) and cardiovascular (CV) mortality
and morbidity [1–4]. Diﬀerent approaches have been used;
however, there seem to be no studies based on data from
individuals without comorbidities obtained from “real-
world” primary care settings and using national electronic
medical records from large databases.
Measuring comorbidity brings about its’ own set of
unique challenges as it sometimes requires the researcher
to detect a diﬀerence between diﬀerent treatment groups.
De Groot et al. [5] listed a number of reasons as to why
oneneedstomeasurecomorbidity:(1)tostrengtheninternal
validity by correcting for confounding, (2) to predict study
outcomes, (3) to identify eﬀect modiﬁcation, and (4) to
improve upon statistical eﬃciency by consolidating multiple
occurring comorbidities into one variable [5]. There are a
number of comorbidity scores available, the most common
of which is to summarize the comorbidity information into
an index or score.
The purpose of this study was to evaluate whether a
large electronic medical record (EMR) database, based on
primary care data, could be used to determine whether
increases in HRs over 3-year followup leads to adverse CV
clinical outcomes among “healthy subjects” identiﬁed by the
Charlson Comorbidity Index (CCI) and Chronic Disease
Score (CDS).2 ISRN Cardiology
2.Methods
2.1. Data Source. This retrospective cohort study used the
General Electric(GE) Centricity(GE Healthcare,GE Health-
careIT,Princeton,NJ)adeidentiﬁedHealthInsurancePorta-
bility and Accountability Act of 1996 (HIPPA)—compliant
EMR database. At the time of the study (2007), the EMR
contained data on more than 8.9 million patients. The GE
EMR database is comprised of data submitted by more than
70 consortium member institutions located in more than 40
states. Consortium members represent a variety of practice
types, ranging from solo practitioners to community clinics,
academic medical centers, and large integrated delivery
networks. Approximately, two thirds of the participating
cliniciansidentifythemselves asprimary carephysicians. The
dataset is comprised of submitted longitudinal patient data
and includes but is not limited to demographic information,
payment type (commercial, Medicare, Medicaid, self-pay,
and unrecognized payment type), enrollment dates, vital
signs, laboratory orders and results, medication list entries
and prescriptions, International Classiﬁcation of Diseases, 9th
Revision, (ICD-9) Clinical Modiﬁcation (ICD-99-CM)d i a g -
nosis codes, and Current Procedure Terminology Version 4
(CPT-4), indicating the type of procedure if provided.
2.2. Study Design and Inclusion Criteria. We conducted a
retrospective cohort study using the GE EMR database.
The study period ranged from 01/01/1996 to 03/30/2007.
“Healthy subjects” were deﬁned as subjects with a lower risk
(i.e., zero) of mortality at baseline based on validated and
widely used comorbidity indices (CCI and CDS). CCI is
based upon ICD-9-CM codes. On the other hand, CDS is
based on prescription information. The “healthy subjects”
were identiﬁed by having a CCI and CDS of 0 at baseline.
The index date was deﬁned as the ﬁrst Health Maintenance
Organization (HMO) activity. CCI and CDS scores were
calculated based on data available in the 395 days prior to
the index date. These healthy subjects were followed for 3
years post-index date. “Healthy subjects” aged 18 years of
age and older with a baseline HR (closest to before index
date or on index date) and at least two post-index HR
readings were identiﬁed between 01/01/1996 to 03/30/2007.
For “healthy subjects” who experienced a CV event, all
HR readings prior to the CV event were considered (i.e.,
HR readings on the day of the CV event were excluded
from analysis). CV events were identiﬁed by the ICD-9-
CM codes (250.xx, 393.xx–398.xx, 401.xx–405.xx, 410.xx,
414.xx–417.xx, 420.xx, 429.xx–438.xx, 440.xx–448.xx,
451.xx–458.xx, 582.xx-583.xx, 585.xx-586.xx, 588.xx-
589.xx, 746.xx-747.xx, 785.1–785.3). The “healthy subjects”
identiﬁed were continuously followed in the EMR during
the study observation period (395 days prior to index date to
3 years post-index date). All HR readings and CCI and CDS
(measured at ﬁrst, second, and third year post-index period)
were included in this model as time varying covariates.
As mentioned, the overall comorbidity burden was
assessed using the CCI and CDS. The CCI is the most
commonly used index to measure and summarize health
conditions. The CCI contains 19 categories of comorbidity,
deﬁned primarily using ICD-9 diagnosis codes [6, 7]. Each
category has an associated weight based on the adjusted risk
of1-yearmortality. Theoverallcomorbidityscorereﬂectsthe
cumulative increased likelihood of 1-year mortality. CCI has
been popularly used and validated in research [8–10].
Another commonly used comorbidity index is the CDS.
The CDS uses pharmacy dispensation information for
speciﬁc drug classes to estimate the burden of comorbidities
[11]. CDS is a risk-adjusted metric based on age, gender,
and history of dispensed drugs. This score is an aggregate
comorbidity measure based on medication use. It has been
proven to be valid in predicting hospitalization, health
resource utilization, and mortality [12–17]. The CDS is the
sum of all chronic diseases identiﬁed from drug therapies
over the full follow-up period.
2.3. Statistical Analysis. After deﬁning and selecting subjects
who met the inclusion and exclusion criteria, descriptive
statistics were utilized to describe the baseline population
and unadjusted outcomes overall. Using a Kaplan-Meier
curve, the survival probability adjusted by heart rate of
subjects overtime was shown (Figure 2). In order to consider
the association between CV events and changes in HR over
36 months along with other covariates after index date,
a Cox proportional hazard regression with an outcome
that is time to CV event anytime during 3-year followup
was used. Among covariates, HR, age, CCI, and CDS were
included as time-varying covariates. All statistical analysis
was performed at a signiﬁcance level of .05 using STATA v.10
(StataCorp, College Station, TX. This project was reviewed
and approved by the University of Utah institutional review
board.
3.Results
3.1. Patient Cohorts. From the GE EMR database between
the years 1996 and 2007, with 3-year followup from index
date, 93,952 healthy subjects (Figure 1) were selected (CCI
= 0a n dC D S= 0). The mean age of subjects at baseline
was 42 (SD: 9.7) years old, and approximately 67% were
female (Table 1). Among those, 32.4% were Caucasian,
approximately 60% had commercial health insurance, and
10.6% were current smokers. Mean HR and BMI of the
healthy subjects at baseline were 75.8bpm (SD: 11.0) and
28.2 (SD: 6.4) kg/m2 (Table 1).
A total of 19,445 healthy subjects (20.7% of 93,952;
mean age 44.4 (SD: 9.4); 63% women) experienced a CV
event anytime during 3-year followup (Table 2). Their mean
follow-up time by CV event was 510 (SD: 313) days after the
index date. The mean HR in this group was 76.3bpm (SD:
11.3).Therewere74,507subjects(79.3%outof93,952;mean
age: 41.4 (SD: 9.7); 68% women) with 3 years of followup
who did not experience a CV event (censored). Mean HR
in this group was 75.7 (SD 10.9) bpm (Table 2). The group
without CV eventsas compared to the group with CV events
were younger (41 years versus 44 years; P value <. 001) and
more were female (68% versus 63%; P value <. 001).ISRN Cardiology 3
GE op p ulation 1996–2007
n = 12,651,234
Age ≥18 years at the start of the study period
n = 8,575,922
(2) Continuously followed 365days pre to
(3) With a baseline HR (close to index date or on index date) and at
(4) Identify healthy subjects based on CCI (= 0) and CDS (=0)
3years post-index date n = 863,852
least two post-HR readings
3-year followup n = 414,430
(index date: date of ﬁrst HMO activity)
3-year followup n = 93,952
Figure 1: Selection of subjects. Notes: GE: General Electric; EMR:
Electronic Medical Record; HR: Heart Rate; CCI: Charlson Co-
morbidity Index; CDS: Chronic Disease Score; HMO: Health
Maintenance Organization.
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Figure 2: Kaplan-Meier survival estimate adjusted by heart rate
over 3 years follow-up (n = 93,952).
3.2. CV Events during 3-Year Followup. Based on the infor-
mation on the subjects who had and had not CV events
during 3-years followup, factors related to CV events were
identiﬁed in Table 3. Most importantly, an increase in HR by
1bpm was associated with a 0.3% increase in relative risk for
a CV event. Exponentially, this equates to an increase in HR
by 5bpm to be associated with a 1% increase in relative risk
for a CV event. In addition, a one-year increase in age raised
Table 1: Baseline characteristics of subjects included (n = 93,952).
Variables Characteristics
N/Mean %/SD Median
Age (as continuous) 42.02 9.68 42
18 to 30 14.98
31 to 40 29.27
41 to 50 32.18
51 to 64 23.57
≥65 0.00
Gender
Female 67.22
Male 32.78
Race/Ethnicity
White 32.38
Black 4.33
Hispanic 1.29
Other 1.95
Unknown 60.05
Insurance type
Commercial 59.58
Medicare 5.4
Medicaid 2.04
Self-pay 1.48
Unknown 31.49
Smokingstatus
Never 26.49
Ever 11.61
Current 10.56
Unknown 51.34
Baseline clinicalparameters
Heart rate 75.84 10.98 76
Total cholesterol 198.97 36.57 197
HDL 54.16 15.88 52
LDL 122.26 32.13 121
SBP 121.22 15.33 120
DBP 76.36 10.03 78
BMI 28.18 6.38 27
Notes: BMI: Body Mass Index; DBP: Diastolic Blood Pressure; SBP:
Systolic Blood Pressure; LDL: Low-density lipoprotein; HDL: High-density
lipoprotein; SD: Standard Deviation.
the hazard ratio by 2.4%. African-American and Hispanic
subjectshadahigherriskofhavingCVeventsascomparedto
Caucasian subjects by 38% and 42%, respectively. Increases
in post-index CCI and CDS were associated with an increase
in hazard ratio by 49% and 22% over 3-year followup,
respectively. Non-smokers had a lower risk of having CV
events than current smokers by approximately 5%.
4.Discussion
This study examined whether increases in HRs over a 3-
year follow-up period leads to adverse CV clinical outcomes4 ISRN Cardiology
Table 2: Comparison in characteristics of subjects with and without CV events during 3 years follow-up.
Variables
Subjects with CV events Subjects without CV events
P value (n = 19,445; 20.7%) (n = 74,507; 79.3%)
Mean SD Median Mean SD Median
Mean followup by CV event 510.08 313.36 487 1095 — —
Age 44.44 9.4 45 41.39 9.66 41 <.001
Female 63% 68% <.001
HR 76.3 11.32 76 75.7 10.89 76 <.001
Notes: CV: Cardiovascular; HR: Heart Rate; SD: Standard Deviation.
Table 3:HazardratioforCoxregressionofCVeventsduring3-year
followup (n = 93,952).
Variable Hazard ratio SE P value 95% CI
HR 1.002 0.001 .000 1.001 1.003
Age 1.024 0.001 .000 1.023 1.026
Gender
Male Base group
Female 0.869 0.011 .000 0.846 0.891
Race
White Base group
Black 1.381 0.041 .000 1.303 1.464
Hispanic 1.419 0.069 .000 1.289 1.561
Others 0.996 0.051 .945 0.902 1.101
Unknown 1.048 0.015 .001 1.019 1.077
Smokingstatus
Current Base group
Former 0.970 0.025 .227 0.922 1.019
Never 0.946 0.021 .012 0.906 0.988
Unknown 0.939 0.019 .002 0.902 0.977
Payment status
Commercial Base group
Medicare 0.986 0.026 .599 0.936 1.039
Medicaid 0.977 0.044 .607 0.895 1.067
Selfpay 1.019 0.055 .722 0.917 1.133
Unknown 1.037 0.014 .010 1.009 1.065
Comorbid index
CCI 1.487 0.011 .000 1.466 1.508
CDS 1.224 0.004 .000 1.216 1.231
among “healthy subjects” identiﬁed by CCI and CDS in the
United States using the GE EMR database.
HR is a commonly measured clinical parameter. How-
ever, the importance of HR may not be generally considered
in treatment decisions. A recent study by Andersson et
al. found that patients with overactive bladder (OAB),
a substantial portion of whom had an increased HR at
baseline, were more likely to experience CV comorbidities
than patients without OAB. In addition, these OAB patients
were more likely to be exposed to medications with antimus-
carinic eﬀects, potentially causing a further increase in HR.
This study found that 39.1% of OAB patients started on
an antimuscarinic medication had an HR over 80bpm [18].
These results suggest that HR and CV comorbiditiesmay not
be considered when making treatment decisions regarding
OAB.
Evidence does exist that suggests HR may inﬂuence
patient outcomes and mortality. Animal studies suggest that
there is a relatively constant number of total heart beats
in a mammal’s lifetime, resulting in an inverse relationship
between lifespan and HR [19]. Benetos et al. found that
after adjusting for major risk factors, men with an elevated
HR (>80bpm) have a decreased probability (>40%) of
reaching 85 years of age compared to men with a low HR
(<60bpm) [20]. Epidemiologic studies have found a rela-
tionship between elevated HR and mortality. In an analysis
of the data from the NHANES Epidemiologic Follow-up
Study,elevatedHRwas foundtobe associated with increased
coronary heart disease and mortality rates [21]. In patients
with coronary artery disease (CAD), increased resting HR
was found to be an independent predictor for all-cause and
cardiovascular mortality [22]. Increased HR in hypertensive
patients has also been shown to increase mortality [23].
This study examined whether increases in HR overtime
lead to CV clinical outcomes among “healthy subjects”
deﬁned by CCI and CDS of zero in the US using an EMR
database.ThisstudyfoundthatanincreaseinHRover3-year
followup was signiﬁcantly related to CV events,showing that
HR is an independent predictor of CV events among healthy
subjects controlling for potential confounders. Possible
mechanisms for this deleterious eﬀect includes accelerated
atherosclerosis, increased arterial rigidity, increased myocar-
dial oxygen consumption, decreased myocardial perfusion
due to shortened diastole, and increased sympathetic and
decreased parasympathetic tone [24, 25].
This study should be considered in light of some limita-
tions. First, this study was based on an EMR; hence, innate
limitations of this type of database, such as coding errors
and systematic factors upcoding, may impact the results of
the study. Second, there might be an underreporting issue
because the dataset was from primary care providers. This
underreporting might bring about a biased result. Third,
we used CCI and CDS only to deﬁne healthy subjects.
However, the study cohort might have been diﬀerent had
we used diﬀerent comorbidity measures to identify healthy
subjects. Lastly, a weakness associated with a comorbidity
indexbasedonaretrospective claimsdatabaseisthattheyare
usually primarily for reimbursement purposes as opposed to
research and, therefore, have varied quality [26, 27].ISRN Cardiology 5
Large long-term hypertension studies have determined
that healthy populations with increased HRs are at increased
risk of CV events and overall mortality. Our retrospective
cohort study using the GE EMR database also indicates that
among “healthy subjects,” elevated HRs are associated with
an increased likelihood of CV events. Our study implies that
modiﬁcation of HR is beneﬁcial for patient care, especially
in patients with higher risk due to hypertension, diabetes,
myocardial infarction, or CV-related chronic illness. Treat-
ment interventions that lower HR such as beta-blockers
and certain calcium channel blockers might be beneﬁcial
to those with higher HR. In addition, due to the potential
risks associated with an increased HR, physicians should be
cautiouswhen prescribingmedicationsthat havetopotential
to increase a patient’s HR.
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